首页> 外文OA文献 >MELK serves as a potent independent biomarker to predict survival of diffuse large B-cell lymphoma patients treated with rituximab-CHOP regimen

【2h】

MELK serves as a potent independent biomarker to predict survival of diffuse large B-cell lymphoma patients treated with rituximab-CHOP regimen

机译：梅尔克用作有效的独立生物标志物，以预测弥漫性大型B细胞淋巴瘤患者的存活率，治疗利妥昔单抗方案

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

AI期刊论文写作 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Y. Zhang; X. Zhou; Y. Li; Y. Xu; X. Wang;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Nuclear coexpression of NF-kappa B subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium [J] . Li Ling, Xu-Monette Zijun Y., Ok Chi Y., Clinical lymphoma, myeloma & leukemia . 2015,第Suppla1期

机译：NF-Kappa B亚基C-Rel和P53突变体的核心共同抑制在用Rituximab-Chop免疫细胞治疗的弥漫性大B细胞淋巴瘤患者中的存活率显着差：International DLBCL rituximab-Chop联盟的报告
2. Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP [J] . ParkS., HanB., ChoJ.W., Nutrition and Cancer: An International Journal . 2014,第1a4期

机译：营养状况对利妥昔单抗-CHOP治疗弥漫性大B细胞淋巴瘤患者生存结局的影响
3. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. [J] . Rimsza LM, Farinha P, Fuchs DA, Leukemia and lymphoma . 2007,第3期

机译：HLA-DR蛋白状态可预测接受MACOP-B化疗方案治疗的弥漫性大B细胞淋巴瘤患者的生存。
4. Survival Prediction in Patients with Diffuse Large B-cell Lymphoma Using Logistic and Neural Network Models [C] . Chin-Chuan Chang, Chien-Hua Chen, Jer-Guang Hsieh, IEEE Eurasia Conference on Biomedical Engineering, Healthcare and Sustainability . 2021

机译：逻辑和神经网络模型弥漫性大B细胞淋巴瘤患者的存活预测
5. Prognostic Biomarkers for Diffuse Large B Cell Lymphoma Patient Survival after Treatment with Chemotherapy: A Retrospective Analysis of 88 Cases [D] . Bushra, Hamama tul. 2019

机译：弥漫性大B细胞淋巴瘤化疗后患者生存的预后生物标志物：88例回顾性分析
6. MicroRNAs are Independent Predictors of Outcome in Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP [O] . Alvaro J. Alencar, Raquel Malumbres, Goldi A. Kozloski, -1

机译：MicroRNA是弥漫性大型B细胞淋巴瘤患者的衍生术的独立预测因子
7. 1 The Interim 18-FDG-PET/CT Failed to Predict the Outcome in Diffuse Large B-Cell Lymphoma Patients Treated at the Diagnosis with Rituximab-CHOP Short title: Interim PET does not predict the outcome in DLBCL [O] . Patrizia Pregno, Marilena Bellò, Barbara Botto, 2016

机译：1临时18-FDG-pET / CT未能预测利妥昔单抗-CHOp诊断治疗弥漫性大B细胞淋巴瘤患者的结果简称：临时pET不能预测DLBCL的结果

MELK serves as a potent independent biomarker to predict survival of diffuse large B-cell lymphoma patients treated with rituximab-CHOP regimen

著录项

引文网络

相似文献

相关主题

期刊订阅